STOCK TITAN
  1. Home
  2. Sec-filings
  3. AGIO
  4. [Form 4] AGIOS PHARMACEUTICALS, INC. Insider Trading Activity

Agios (NASDAQ: AGIO) director reports RSU exercise and new equity grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

AGIOS PHARMACEUTICALS director Cynthia Smith reported equity compensation activity and an option exercise. On June 18, 2026, she exercised restricted stock units covering 2,816 shares of common stock, bringing her direct common stock holdings to 15,230 shares after the transaction.

She also received 14,950 stock options with an exercise price of $34.16 per share that vest in full on June 18, 2027, and 2,927 new restricted stock units that also vest on June 18, 2027. Earlier restricted stock units granted on June 18, 2025 vested in full on June 18, 2026, and the vested shares will be delivered within three business days after vesting.

Positive

  • None.

Negative

  • None.
Insider Smith Cynthia
Role null
Type Security Shares Price Value
Exercise Restricted stock units 2,816 $0.00 --
Grant/Award Restricted stock units 2,927 $0.00 --
Grant/Award Stock options (right to buy) 14,950 $0.00 --
Exercise Common stock 2,816 $0.00 --
Holdings After Transaction: Restricted stock units — 0 shares (Direct, null); Stock options (right to buy) — 14,950 shares (Direct, null); Common stock — 15,230 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.
RSUs exercised into common stock 2,816 shares Restricted stock units converted on June 18, 2026
Common shares held after transaction 15,230 shares Direct ownership after June 18, 2026 transactions
New stock options granted 14,950 options Grant date June 18, 2026; vesting June 18, 2027
Stock option exercise price $34.16 per share Exercise price for 14,950 stock options
Option expiration date June 18, 2036 Expiration for newly granted stock options
New restricted stock units granted 2,927 RSUs Granted June 18, 2026; vesting June 18, 2027
restricted stock units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock options (right to buy) financial
"Stock options (right to buy) with an exercise price of $34.16"
Exercise or conversion of derivative security financial
"transaction code description: Exercise or conversion of derivative security"
Grant, award, or other acquisition financial
"transaction code description: Grant, award, or other acquisition"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Smith Cynthia
(Last)(First)(Middle)
C/O AGIOS PHARMACEUTICALS, INC.
88 SIDNEY STREET
(Street)
CAMBRIDGE MASSACHUSETTS 02139
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common stock06/18/2026M2,816A$015,230D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted stock units(1)06/18/2026M2,816 (2) (2)Common stock2,816$00D
Restricted stock units(1)06/18/2026A2,927 (3) (3)Common stock2,927$02,927D
Stock options (right to buy)$34.1606/18/2026A14,950 (4)06/18/2036Common stock14,950$014,950D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
2. The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
3. The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
4. These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.
Remarks:
/s/ William Cook, as attorney-in-fact for Cynthia Smith06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did AGIOS (AGIO) director Cynthia Smith report in this Form 4?

Cynthia Smith reported exercising restricted stock units into 2,816 shares of Agios common stock and receiving new grants of 14,950 stock options and 2,927 restricted stock units. These are equity compensation-related transactions, not open-market share purchases or sales.

How many AGIOS (AGIO) shares does Cynthia Smith hold after these transactions?

After exercising restricted stock units into common stock, Cynthia Smith directly holds 15,230 shares of Agios common stock. This figure reflects her reported direct ownership following the June 18, 2026 transactions disclosed in the Form 4 filing.

What stock options were granted to Cynthia Smith by AGIOS (AGIO)?

Cynthia Smith received 14,950 stock options with an exercise price of $34.16 per share, expiring on June 18, 2036. The options vest as to 100% of the underlying shares on June 18, 2027, according to the Form 4 footnote disclosure.

What restricted stock units did Cynthia Smith receive from AGIOS (AGIO)?

She was granted 2,927 restricted stock units on June 18, 2026, each representing a right to receive one share of common stock. These units will vest in full on June 18, 2027, with vested shares delivered within three business days after vesting.

Were Cynthia Smith’s AGIOS (AGIO) transactions open-market buys or sells?

No, the disclosed transactions are equity compensation-related. They include an exercise or conversion of restricted stock units into common stock and grants of stock options and restricted stock units. The Form 4 shows no open-market purchases or sales of Agios shares.